Relevance of NR1I2 Variants on Carbamazepine Therapy in Mexican Mestizos with Epilepsy at a Tertiary-Care Hospital

References

• WHO . Model list of essential medicines (2019). http://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1
   Google Scholar
• Gierbolini J , GiarratanoM , BenbadisSR. Carbamazepine-related antiepileptic drugs for the treatment of epilepsy-a comparative review. Expert Opin. Pharmacother.17(7), 885–888 (2016).
   PubMed Web of Science ®Google Scholar
• Porter R , MeldrumB. Fármacos anticonvulsivos. In: Farmacología Básica y Clínica.KatzungB, MastersS, TrevorA ( Eds). The McGraw-Hill Companies, Inc., USA, 397–407 (2010).
   Google Scholar
• Bertilsson L , TomsonT. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. Clin. Pharmacokinet.11(3), 177–198 (1986).
   PubMed Web of Science ®Google Scholar
• Burton M , ShawL , SchentagJ , EvansWE. Applied pharmacokinetics & pharmacodynamics principles of therapeutic drug monitoring. Am. J. Pharm. Educ.70(6), 148 (2006).
   Google Scholar
• Patsalos PN . Antiepileptic Drug Interactions.Springer, London, UK, 15–21 (2015).
   Google Scholar
• Thorn CF , LeckbandSG , KelsoeJet al. PharmGKB summary: carbamazepine pathway. Pharmacogenet. Genomics21(12), 906–910 (2011).
   PubMed Web of Science ®Google Scholar
• Monroy-Jaramillo N , Fricke-GalindoI , Ortega-VázquezA , Jung-CookH , LLerenaA , López-LópezM. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response. Drug Metabol. Drug Interact.29(2), 67–79 (2014).
   PubMedGoogle Scholar
• Awasthi S , HalleneKL , FazioVet al. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci.6, 61 (2005).
   PubMed Web of Science ®Google Scholar
• Kim W-J , LeeJH , YiJet al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics20(4), 249–256 (2010).
   PubMed Web of Science ®Google Scholar
• Marino SE , BirnbaumAK , LeppikIEet al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin. Pharmacol. Ther.91(3), 483–488 (2012).
   PubMed Web of Science ®Google Scholar
• Chbili C , SaguemS , ChbiliCet al. Clinical research The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients. Arch. Med. Sci.13, 353–360 (2017).
   PubMed Web of Science ®Google Scholar
• Iannaccone T , SellittoC , ManzoVet al. Pharmacogenetics of carbamazepine and valproate: focus on polymorphisms of drug metabolizing enzymes and transporters. Pharmaceuticals (Basel)14(3), 204 (2021).
   PubMedGoogle Scholar
• Fricke-Galindo I , Ortega-VázquezA , Monroy-JaramilloNet al. Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics17(17), 1913–1930 (2016).
   PubMed Web of Science ®Google Scholar
• Chbili C , FathallahN , LaouaniAet al. Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients. J. Neurogenet.30(1), 16–21 (2016).
   PubMed Web of Science ®Google Scholar
• Puranik YG , BirnbaumAK , MarinoSEet al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics14(1), 35–45 (2013).
   PubMed Web of Science ®Google Scholar
• Ma C-L , JiaoZ , WuX-Y , HongZ , WuZ-Y , ZhongM-K. Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. Pharmacogenomics16(13), 1499–1512 (2015).
   PubMed Web of Science ®Google Scholar
• Hu T , ZengX , TianT , LiuJ. Association of EPHX1 polymorphisms with plasma concentration of carbamazepine in epileptic patients: systematic review and meta-analysis. J. Clin. Neurosci.91, 159–171 (2021).
   PubMed Web of Science ®Google Scholar
• Zhao GX , ZhangZ , CaiWK , ShenML , WangP , HeGH. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: a meta-analysis. Epilepsy Res.173, 106615 (2021).
   PubMed Web of Science ®Google Scholar
• Subenthiran S , AbdullahNR , JosephJPet al. Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. PLoS ONE8(5), e64827 (2013).
   PubMed Web of Science ®Google Scholar
• Qu J , ZhouB-T , YinJ-Yet al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci. Ther.18(8), 647–651 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou B , ZhouQ , YinJ , LiG , XuX , QuJ. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin. Exp. Pharmacol. Physiol.39, 379–384 (2012).
   PubMed Web of Science ®Google Scholar
• Lakhan R , KumariR , MisraUK , KalitaJ , PradhanS , MittalB. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol.68(2), 214–220 (2009).
   PubMed Web of Science ®Google Scholar
• Sterjev Z , KitevaG , CvetkovskaEet al. Influence of the SCN1A IVS5N + 5 G >A polymorphism on therapy with carbamazepine for epilepsy. Balkan J. Med. Genet.15(1), 19–24 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang X , LiuJ , YeJ. Association between SCN1A polymorphism and carbamazepine responsiveness in epilepsy: a meta-analysis. Epilepsy Res.176, 106627 (2021).
   PubMed Web of Science ®Google Scholar
• Lamba J , LambaV , SchuetzE. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab.6(4), 369–383 (2005).
   PubMed Web of Science ®Google Scholar
• Lamba J , LambaV , StromS , VenkataramananR , SchuetzE. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos.36(1), 169–181 (2008).
   PubMed Web of Science ®Google Scholar
• Saruwatari J , YoshidaS , TsudaYet al. Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction. Pharmacogenet. Genomics24(3), 162–171 (2014).
   PubMed Web of Science ®Google Scholar
• Moreno-Estrada A , GignouxCR , Fernández-LópezJCet al. Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science344(6189), 1280–1285 (2014).
   PubMed Web of Science ®Google Scholar
• Martínez-Juárez IE , Lóopez-ZapataR , Gómez-AriasBet al. Epilepsia farmacorresistente: uso de la nueva definición y factores de riesgo relacionados. Estudio en población Mexicana de un centro de tercer nivel. Rev. Neurol.54(3), 159–166 (2012).
   PubMedGoogle Scholar
• Barrett JC , FryB , MallerJ , DalyMJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics21(2), 263–265 (2005).
   PubMed Web of Science ®Google Scholar
• Purcell S , NealeB , Todd-BrownKet al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet.81(3), 559–575 (2007).
   PubMed Web of Science ®Google Scholar
• Faul F , ErdfelderE , LangA-G , BuchnerA. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods.39(2), 175–191 (2007).
   PubMed Web of Science ®Google Scholar
• Faul F , ErdfelderE , BuchnerA , LangA-G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav. Res. Methods.41(4), 1149–1160 (2009).
   PubMed Web of Science ®Google Scholar
• Besag FM , BerryDJ , PoolF , NewberyJE , SubelB. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?Epilepsia39(2), 183–187 (1998).
   PubMed Web of Science ®Google Scholar
• Warner T , PatsalosPN , PrevettM , ElyasAA , DuncanJS. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res.11(2), 147–150 (1992).
   PubMed Web of Science ®Google Scholar
• Weiner CP , MasonC. Drugs for Pregnant and Lactating Women.Elsevier, The Netherlands, 91–186 (2019).
   Google Scholar
• Kliewer SA , GoodwinB , WillsonTM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev.23(5), 687–702 (2002).
   PubMed Web of Science ®Google Scholar
• Tolson AH , WangH. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliv. Rev.62(13), 1238–1249 (2010).
   PubMed Web of Science ®Google Scholar
• Ke X-J , ChengY-F , YuN , DiQ. Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-κB activity in the bEnd.3 cells. Neurosci. Lett.690, 48–55 (2019).
   PubMed Web of Science ®Google Scholar
• Yu N , ZhangY-F , ZhangK , ChengY-F , MaH-Y , DiQ. Pregnane X receptor not nuclear factor-kappa B up-regulates P-glycoprotein expression in the brain of chronic epileptic rats induced by kainic acid. Neurochem. Res.42(8), 2167–2177 (2017).
   PubMed Web of Science ®Google Scholar
• Oscarson M , ZangerUM , RifkiOF , KleinK , EichelbaumM , MeyerUA. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther.80(5), (2006).
   PubMed Web of Science ®Google Scholar
• Hustert E , ZibatA , Presecan-SiedelEet al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos.29(11), 1454–1459 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang J , KuehlP , GreenEDet al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics11(7), 555–572 (2001).
   PubMedGoogle Scholar
• Hung C-C , JenTai J , KaoP-J , LinM-S , LiouH-H. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics8(9), 1151–1158 (2007).
   PubMed Web of Science ®Google Scholar
• Haerian BS , MohamedE , LimKet al. Association of ABCB1 and NR1I2 polymorphisms with response to carbamazepine in Malaysian epilepsy patients. FASEB J.24(Suppl. 1), 756.3–756.3 (2010).
   Google Scholar
• Abe T , SeoT , IshitsuT , NakagawaT , HoriM , NakagawaK. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol.66(2), 304–307 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou B-T , ZhouQ-H , YinJ-Yet al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci. Ther.18(7), 566–572 (2012).
   PubMed Web of Science ®Google Scholar
• Tate SK , DepondtC , SisodiyaSMet al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS102(15), 5507–5512 (2005).
   PubMed Web of Science ®Google Scholar
• Hung C-C , ChangW-L , HoJ-Let al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics13(2), 159–169 (2012).
   PubMed Web of Science ®Google Scholar
• Makmor-Bakry M , SillsGJ , HitirisN , ButlerE , WilsonEA , BrodieMJ. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin. Neuropharmacol.32(4), 205–212 (2009).
   PubMed Web of Science ®Google Scholar